NIAC recommends the passive immunisation with nirsevimab of all infants who are born during the RSV season. These infants should receive nirsevimab ideally prior to discharge home from a maternity hospital.
NIAC recommends the passive immunisation with nirsevimab of all *high-risk infantsaged ≤12 months at the start of their firstRSV season. These infants should receive nirsevimab prior to the start of the RSV season.
NIAC recommends the passive immunisation with nirsevimab of all infants who are aged ≤6 months at the start of the RSV season. These infants should receive nirsevimab prior to the start of the RSV season.
NIAC recommends the passive immunisation with nirsevimab of all ex-preterm infants under24 months of age with†Chronic Lung Disease in their second season RSV season. Infants who will be severely immunocompromised during the RSV season may also be considered for nirsevimab in consultation with their treating specialist. These infants should receive nirsevimab prior to the start of the RSV season.
- Recommendation
- Europe
- Ireland
- RSV (Respiratory syncytial virus)
